Synthesis and selective inhibition of human monoamine oxidases of a large scaffold of (4,5-substituted-thiazol-2-yl)hydrazones

A large class of (4,5-substituted-thiazol-2-yl)hydrazone derivatives (1–66) was synthesized in good yield (82–99%) and characterized by elemental analysis and 1H NMR studies. The compounds were assayed for their in vitro human monoamine oxidase inhibitory activity and selectivity. Most of them showed IC50 values in the micromolar range. Our aim was to evaluate the importance of a bulky group at C2, C4, and C5 positions of the thiazole nucleus in modulating the biological activity of this scaffold.

[1]  A. Mattevi,et al.  Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. , 2009, Biochemistry.

[2]  S. Carradori,et al.  Synthesis and biological evaluation of novel conjugated coumarin‐thiazole systems , 2009 .

[3]  J. Shih,et al.  Monoamine oxidase inactivation: from pathophysiology to therapeutics. , 2008, Advanced drug delivery reviews.

[4]  S. Carradori,et al.  Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones. , 2008, Journal of medicinal chemistry.

[5]  E. Yamashita,et al.  Structure of human monoamine oxidase A at 2.2-Å resolution: The control of opening the entry for substrates/inhibitors , 2008, Proceedings of the National Academy of Sciences.

[6]  S. Carradori,et al.  High-performance liquid chromatographic separation of enantiomers and diastereomers of 2-methylcyclohexanone thiosemicarbazone, and determination of absolute configuration and configurational stability. , 2007, Journal of chromatography. A.

[7]  A. Mattevi,et al.  New insights into the structures and functions of human monoamine oxidases A and B , 2007, Journal of Neural Transmission.

[8]  D. Secci,et al.  Selective inhibitory activity against MAO and molecular modeling studies of 2-thiazolylhydrazone derivatives. , 2007, Journal of medicinal chemistry.

[9]  D. Guay.  Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. , 2006, The American journal of geriatric pharmacotherapy.

[10]  Francisco Orallo,et al.  Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. , 2006, Biochemical and biophysical research communications.

[11]  Keith F. Tipton,et al.  The therapeutic potential of monoamine oxidase inhibitors , 2006, Nature Reviews Neuroscience.

[12]  S. Carradori,et al.  Recent development of monoamine oxidase inhibitors , 2005 .

[13]  A. Mattevi,et al.  Demonstration of Isoleucine 199 as a Structural Determinant for the Selective Inhibition of Human Monoamine Oxidase B by Specific Reversible Inhibitors* , 2005, Journal of Biological Chemistry.

[14]  M. Carreiras,et al.  Recent approaches to novel anti-Alzheimer therapy. , 2004, Current pharmaceutical design.

[15]  P. Riederer,et al.  Clinical applications of MAO-inhibitors. , 2004, Current medicinal chemistry.

[16]  A. Mattevi,et al.  Structure and mechanism of monoamine oxidase. , 2004, Current medicinal chemistry.

[17]  R. Benassi,et al.  Conformational analysis of hydrazones. 1H dynamic nuclear magnetic resonance and solvent effects in aryl‐ and 2‐furylaldehyde ethylaminoacetylhydrazones , 1982 .